Document 0743
 DOCN  M9480743
 TI    Three open-label studies of oral interferon alpha in the treatment of
       HIV disease.
 DT    9410
 AU    Jordan WC; Oasis (AIDS) Clinic, Martin Luther King, Jr General
       Hospital,; Drew University of Medicine and Science, Los Angeles,
       California.
 SO    J Natl Med Assoc. 1994 Apr;86(4):257-62. Unique Identifier : AIDSLINE
       MED/94315636
 AB    Three open-label studies were conducted in which natural human
       interferon-alpha (nHuIFN-alpha) was given orally to human
       immunodeficiency virus (HIV)-infected patients at a daily dosage of 150
       IU for 12 months in an attempt to assess the effects of this treatment
       on their CD4+ cell counts. In the first study, 110 patients received
       nHuIFN-alpha, and 142 patients received nHuIFN-alpha and azidothymidine
       (AZT). At 12 months, patients given nHuIFN-alpha alone had a mean
       increase of 14% in their CD4+ counts, although the mean increase in
       absolute CD4+ count was similar between the groups. Blacks in this study
       were more likely to experience an increase in CD4+ count than other
       ethnic groups (P < 0.001). In the second study, 40 black, male
       homosexuals with CD4+ count between 350 and 500/mm3 were enrolled in
       groups of 10 to receive either nHuIFN-alpha or AZT, or both nHuIFN-alpha
       and AZT, or nothing (untreated controls). At 12 months, the mean CD4+
       counts of the patients in the group given nHuIFN-alpha alone were
       significantly higher than the mean CD4+ counts in both the group given
       AZT alone and the untreated controls (P < 0.01). In the third study, 38
       patients with CD4+ cell counts > 700/mm3 were enrolled in groups of 19,
       matched by gender and ethnic group, to receive nHuIFN-alpha or nothing
       (untreated controls). Patients given nHuIFN-alpha experienced a mean
       increase of 12% in their CD4+ counts by the end of the 12-month
       study.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Administration, Oral  Adult  Female  Human  HIV
       Seropositivity/ETHNOLOGY/*THERAPY  Interferon-alpha/*THERAPEUTIC USE
       Male  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).